Since its emergence, SARS-CoV-2 has been continuously evolving, hampering the
effectiveness of current vaccines against COVID-19. mAbs can be used to treat patients at …

Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of …

Background Monoclonal antibodies (mAbs) targeting the spike of SARS-CoV-2 prevent
severe COVID-19. Omicron subvariants BQ. 1.1 and XBB. 1.5 evade neutralization of …

Anti-SARS-CoV-2 vaccination leads to the production of neutralizing as well as non-
neutralizing antibodies. In the current study, we investigated the temporal dynamics of both …

The immune effector mechanisms involved in protecting against severe COVID-19 infection
in elderly nursing home residents following vaccination or natural infection are not well …

Abstract mAbs are highly indispensable tools for diagnostic, prophylactic, and therapeutic
applications. The first technique, hybridoma technology, was based on fusion of B …

The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) heavily burdened the entire world. Despite a prompt generation of vaccines …

The integration of multi-'omic datasets into complex systems-wide assessments has become
a mainstay in immunologic investigation. This focus on high-dimensional data collection and …

Vaccine-induced mucosal immunity and broad protective capacity against various severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remain inadequate …

With the increasing momentum and success of monoclonal antibody therapy in conventional
medical practices, there is a revived emphasis on the development of monoclonal …